PharmaCyte Biotech, Inc.
PMCB
$0.94
$0.044.34%
NASDAQ
| 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 20.61M | 18.05M | 15.54M | 16.76M | 20.84M |
| Total Receivables | -- | -- | 3.70M | -- | -- |
| Inventory | -- | -- | -- | -- | -- |
| Prepaid Expenses | 503.10K | 238.20K | 223.80K | 207.40K | 493.20K |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | 1.91M | 820.00K | 2.92M | -- | -- |
| Total Current Assets | 23.02M | 19.11M | 22.38M | 16.96M | 21.33M |
|
|
|||||
| Total Current Assets | 23.02M | 19.11M | 22.38M | 16.96M | 21.33M |
| Net Property, Plant & Equipment | -- | -- | -- | -- | -- |
| Long-term Investments | -- | -- | -- | -- | -- |
| Goodwill | -- | -- | -- | -- | -- |
| Total Other Intangibles | 1.55M | 1.55M | 1.55M | 1.55M | 1.55M |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | 10.66M | 4.82M | 8.77M | 6.69M | 7.36M |
| Total Assets | 55.98M | 45.11M | 55.17M | 43.83M | 55.10M |
|
|
|||||
| Total Accounts Payable | 1.02M | 465.20K | 399.20K | 484.90K | 348.60K |
| Total Accrued Expenses | 345.70K | 345.70K | 521.10K | 709.40K | 707.20K |
| Short-term Debt | -- | -- | -- | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Liabilities | 210.40K | 250.00K | 1.99M | -- | 3.72M |
| Total Other Current Liabilities | 210.40K | 250.00K | 1.99M | -- | 3.72M |
| Total Current Liabilities | 1.58M | 1.06M | 2.91M | 1.19M | 4.78M |
|
|
|||||
| Total Current Liabilities | 1.58M | 1.06M | 2.91M | 1.19M | 4.78M |
| Long-Term Debt | -- | -- | -- | -- | -- |
| Short-term Debt | -- | -- | -- | -- | -- |
| Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | 17.85M | 458.00K | 363.00K | 2.38M | 6.87M |
| Total Liabilities | 19.42M | 1.52M | 3.28M | 3.58M | 11.65M |
|
|
|||||
| Common Stock & APIC | 180.61M | 181.55M | 181.49M | 181.43M | 181.36M |
| Retained Earnings | -100.75M | -93.33M | -84.97M | -96.72M | -93.67M |
| Treasury Stock & Other | -44.22M | -44.63M | -44.63M | -44.46M | -44.23M |
| Total Common Equity | 35.65M | 43.59M | 51.89M | 40.25M | 43.45M |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | 902.00K | -- | -- | -- | -- |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | 902.00K | -- | -- | -- | -- |
|
|
|||||
| Total Common Equity | 35.65M | 43.59M | 51.89M | 40.25M | 43.45M |
| Total Preferred Equity | 902.00K | -- | -- | -- | -- |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | 36.55M | 43.59M | 51.89M | 40.25M | 43.45M |
|
|
|||||